紫云膏外用治疗特应性皮炎患者:一项随机对照试验的研究方案
这是一项随机、双盲、安慰剂对照、单中心、IIa期临床试验方案,旨在评估紫云膏(Jaungo)在特应性皮炎(AD)患者中的安全性、初步疗效和剂量反应。研究计划纳入34例AD患者,随机分为治疗1组(每日两次紫云膏)、治疗2组(每日一次紫云膏加一次安慰剂软膏)和安慰剂组(每日两次安慰剂软膏),疗程3周,评估湿疹面积与严重度指数、特应性皮炎评分指数、皮肤病生活质量指数、经皮水分丢失、总IgE、嗜酸性粒细胞计数及IL-17、IL-22、IFN-γ水平等指标。
要点
- 紫云膏由紫草根、大当归根及三种载体油组成,是韩国获批用于皮肤干燥的草药软膏。
- 本研究为IIa期随机双盲安慰剂对照试验,计划纳入34例AD患者,分三组平行对照,疗程3周。
- 主要评估指标包括湿疹面积与严重度指数、特应性皮炎评分指数、皮肤病生活质量指数及多项实验室指标。
核心结论
- 该试验旨在确定紫云膏在AD中的疗效和安全性,为紫云膏治疗特定AD症状提供证据。
研究设计与样本
- 随机、双盲、安慰剂对照、单中心、IIa期临床试验,计划纳入34例AD患者,随机分配至治疗1组、治疗2组和安慰剂组三个平行组。
- 治疗1组每日两次外用紫云膏;治疗2组每日一次外用紫云膏并每日一次外用安慰剂软膏(分开使用);安慰剂组每日两次外用安慰剂软膏;疗程共3周。
- 研究方案经庆熙大学韩医学院机构审查委员会(编号KOMCIRB-160617-HR-027)和韩国食品药品管理局(编号30907)批准。
关键数值与推荐
- 治疗1组每日两次外用紫云膏,治疗2组每日一次外用紫云膏加一次安慰剂软膏,安慰剂组每日两次外用安慰剂软膏,疗程均为3周。
- 评估指标包括湿疹面积与严重度指数、特应性皮炎评分指数、皮肤病生活质量指数、经皮水分丢失、总IgE水平、嗜酸性粒细胞计数以及IL-17、IL-22和IFN-γ水平。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is a common pruritic inflammatory skin disease with increasing prevalence. It can manifest with many different clinical phenotypes; however, in its chronic stage, hyperpigmentation, excoriation, lichenification, and dryness are the main symptoms. Jaungo comprises two herbs, Lithospermi radix and Angelica gigantis radix, and three carrier oils, and is an approved herbal ointment for xerosis cutis in Korea. In past studies, we demonstrated that Jaungo had anti-inflammatory and antiallergic activity in in vitro and in vivo AD models; however, there are few relevant randomized controlled clinical trials on Jaungo in AD. METHODS/DESIGN: A randomized, double-blind, placebo-controlled, single-center, phase IIa clinical trial was designed to investigate the safety, preliminary efficacy, and dose response of Jaungo in AD. The study protocol was approved by the Institutional Review Boards of the Kyung Hee University Korean Medicine Hospital (No. KOMCIRB-160617-HR-027) and the Korea Food and Drug Administration (No. 30907). The study aims to enroll 34 AD patients to be randomly distributed among three parallel groups: treatment 1, treatment 2, and the placebo group. Treatment group 1 applies Jaungo twice a day, while treatment group 2 applies Jaungo and the placebo ointment once a day, separately, and the placebo group applies the placebo ointment twice a day, for a total of 3 weeks each. Participants will be evaluated for eczema before and after the application of the ointments based on several parameters including the Eczema Area and Severity Index, the SCORing of Atopic Dermatitis Index, the Dermatology Life Quality Index, transepidermal water loss, total IgE level, eosinophil count, and IL-17, IL-22, and IFN-γ levels. DISCUSSION: The trial is currently ongoing and the enrollment of subjects has been initiated. There is an urgent need to develop a drug for the treatment of dry, hyperpigmented, scaly, and thickened skin in chronic-stage AD. This study will determine the efficacy and safety of Jaungo in AD, providing evidence for specific AD symptoms treated by Jaungo. TRIAL REGISTRATION: Clinical Trials.gov, identifier: NCT02900131 . Registered on 2 September 2016. Korea Clinical Research Information Service, identifier: KCT0002060 . Registered on 22 July 2016.
引用
- Yun Y, Ko Y, Ahn JH, et al. Topical application of Jaungo in atopic dermatitis patients: study protocol for a randomized, controlled trial. Trials. 2017. PMID: 28403910. doi:10.1186/s13063-017-1920-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。